No Means No: Genzyme Responds To Sanofi's Hostile Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi CEO Viehbacher indicated a price of $69- to $80-per-share would be acceptable, Genzyme reveals in an SEC filing.
You may also be interested in...
Genzyme Jumps First Consent Decree Hurdle
Genzyme - out to assure investors and hostile bidder Sanofi that its business is back on track - says it successfully met the first requirement of an FDA consent decree.
Genzyme Jumps First Consent Decree Hurdle
Genzyme - out to assure investors and hostile bidder Sanofi that its business is back on track - says it successfully met the first requirement of an FDA consent decree.
Sanofi Forces Genzyme's Hand With Hostile Bid
With no white knight in Genzyme's corner, Sanofi commences a tender offer for Genzyme at $69-per-share.